Latest News for: takeda
Edit
Initial Statement of Beneficial Ownership (Form 3) (Takeda Pharmaceutical Co Ltd)
Public Technologies 18 Mar 2026
Edit
Egypt steps up research cooperation with Takeda Pharmaceutical
Daily News Egypt 17 Mar 2026
Egypt is intensifying efforts to strengthen pharmaceutical research and innovation through closer cooperation with Takeda Pharmaceutical Company, as part of a broader strategy to enhance the country’s healthcare and drug development ecosystem.
Edit
Rixubis (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, ...
Nasdaq Globe Newswire 13 Mar 2026
.
Edit
Feiba VH (Takeda Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, ...
Nasdaq Globe Newswire 10 Mar 2026
.
Edit
Flexbumin (Takeda Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, ...
Nasdaq Globe Newswire 10 Mar 2026
Regional growth. North America leads, Asia-Pacific fastest-growing ... Regional growth ... .
Edit
Feiba NF (Takeda Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, ...
Nasdaq Globe Newswire 10 Mar 2026
These factors drive growth and enhance treatment accessibility in hemophilia care ... .
Edit
ADZYNMA (Takeda Pharmaceutical: ADAMTS13, recombinant-krhn) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & ...
Nasdaq Globe Newswire 10 Mar 2026
Edit
Hemofil M (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, ...
Nasdaq Globe Newswire 10 Mar 2026
Challenges like tariffs encourage investment in local plasma processing, promoting sustainable growth ... .
Edit
Lowey Dannenberg, P.C., Announces Notice of Class Action If You Paid for Some or All ...
Bennington Banner 10 Mar 2026
WHITE PLAINS, N.Y., March 9, 2026 /PRNewswire/ -- ....
Edit
Caledonian Record
02 Mar 2026
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants ...
Caledonian Record
02 Mar 2026
Edit
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera (Form 6-K) (Takeda Pharmaceutical Co Ltd)
Public Technologies 02 Mar 2026
1 Takeda and Protagonist Announce U.S ... Takeda and Protagonist Announce U.S ... OSAKA, Japan, March 2, 2026 - Takeda (TSE.4502/NYSE.TAK) ("Takeda") and Protagonist Therapeutics, Inc ... [email protected] ... [email protected].
Edit
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera (Takeda Pharmaceutical Co Ltd)
Public Technologies 02 Mar 2026
OSAKA, Japan, CAMBRIDGE, Massachusetts and NEWARK, California, March 2, 2026 - Takeda (TSE.4502/NYSE.TAK) and Protagonist Therapeutics, Inc ... ## About Takeda Takeda is focused on creating better health for people and a brighter future for the world.
Edit
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Pharmiweb 02 Mar 2026
... document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release.
- 1
- 2
- Next page »